CIK 0001124105
- Accelerated filer
- Smaller reporting company
GYRE THERAPEUTICS, INC.
Sign in to watch- Ticker
- GYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 562020050
- Phone
- +1 858-284-0115
- Business address
- 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
- Former names
- CATALYST BIOSCIENCES, INC., TARGACEPT INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-01-16 | SELICK HAROLD E Director | Returned to the company · Stock Option (Right to Buy) | −450 | 0 | ||
| 2018-01-16 | SELICK HAROLD E Director | Grant or award · Stock Option (Right to Buy) | +450 | 450 | ||
| 2018-01-16 | SELICK HAROLD E Director | Returned to the company · Stock Option (Right to Buy) | −500 | 0 | ||
| 2018-01-16 | SELICK HAROLD E Director | Grant or award · Stock Option (Right to Buy) | +500 | 500 | ||
| 2018-01-16 | SELICK HAROLD E Director | Returned to the company · Stock Option (Right to Buy) | −10,000 | 0 | ||
| 2018-01-16 | SELICK HAROLD E Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2018-01-12 | USMAN NASSIM President and CEO | Grant or award · Stock Option(Right to Buy) | +95,000 | 95,000 | ||
| 2018-01-12 | Payne Fletcher Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2018-01-12 | Levy Howard Chief Medical Officer | Grant or award · Stock Option(Right to Buy) | +33,000 | 33,000 | ||
| 2018-01-02 | Williams Eddie Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-12-20 | Richard John P Director | Other disposition · Redeemable Convertible Note | −0 | |||
| 2017-10-25 | Hunt Andrea Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-07-13 | Richard John P Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-07-13 | SELICK HAROLD E Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-07-13 | LAWLOR AUGUSTINE Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-07-13 | HILL STEPHEN A Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-07-13 | DESOUZA ERROL B Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-07-11 | Levy Howard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2017-07-11 | Payne Fletcher Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2017-07-11 | USMAN NASSIM President & CEO | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 |
Page 22 of 24 · 471 trades